Retatrutide Results: What Changed Between Phase 2 and Phase 3?

Retatrutide results are often reduced to a single percentage. That loses the details that make the number interpretable: who entered the study, what outcome was measured, when it was measured and how the analysis handled people who stopped treatment or needed other care. A result from a phase 2 obesity study is not interchangeable with a later phase 3 result in people with type 2 diabetes, even when the molecule has the same name.

The published record now includes the 2023 phase 2 obesity trial and two major phase 3 reports published in 2026. These studies provide a progression of evidence rather than three versions of one experiment. They differ in size, duration and participants. Their estimates should remain attached to those differences. Larger, longer trials can answer more questions, but they do not remove every uncertainty or turn an average result into an individual forecast.

This guide follows the evidence through those reports. It explains why a week-48 secondary result needs its time point, why the treatment-regimen approach matters in the phase 3 papers, and why liver-fat findings belong in a different column from bodyweight findings. Echo’s research hub supplies the receptor background; the results discussed here come from the original clinical publications. Read together, those sources offer a more useful picture than a timeline built from promotional headlines alone.